Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Entrectinib is a targeted therapy for solid tumors positive for NTRK gene fusions and ROS1-positive non-small cell lung cancer. Its price varies depending on the region, dosage spe···【more】
Article source：Captain MedicineRelease date：2026-03-09Recommended：163
Lucius Pharmaceuticals Osimertinib is a targeted therapy used to treat non-small cell lung cancer. Its common side effects include skin reactions (rash, dryness), gastrointestinal ···【more】
Article source：Captain MedicineRelease date：2026-03-06Recommended：157
The price of Osimertinib varies depending on specifications, region, and medical insurance policies. Currently, the cost per box ranges from thousands to tens of thousands of yuan.···【more】
Article source：Captain MedicineRelease date：2026-03-06Recommended：156
The price of osimertinib varies depending on specifications, region, purchasing channels, and medical insurance policies. For specific prices in the domestic market, it is necessar···【more】
Article source：Captain MedicineRelease date：2026-03-06Recommended：246
Osimertinib is a targeted therapy used to treat specific types of non-small cell lung cancer. Its price in China varies due to factors such as dosage form, purchasing channel, and ···【more】
Article source：Captain MedicineRelease date：2026-03-06Recommended：238
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 tyrosine kinase inhibitor developed by Pfizer Inc., USA.Lorlatinib Side Effects Requiring Immediate Medical At···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：198
In September 2018, Lorlatinib was first approved for marketing in Japan, followed by approval from the U.S. Food and Drug Administration (FDA) in November of the same year, and the···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：171
On October 12, 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Encorafenib in combination with Binimetinib for the treatment of adult pati···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：170
In June 2018, the U.S. Food and Drug Administration (FDA) approved Binimetinib for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. In Octob···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：171
Whether long-term administration of stiripentol is required depends on the control of the condition and the physician’s evaluation. This medication is mainly used for refractory ep···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：203
Whether the side effects of stiripentol diminish over time varies between individuals and depends on the specific type of adverse reaction. Some patients may experience short-term ···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：176
Stiripentol is an adjuvant drug commonly used for drug-resistant epilepsy (such as Dravet syndrome). Its common side effects include drowsiness, loss of appetite, fatigue, weight c···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：175
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended：[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended：[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended：[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended：[list:visits]2026-16-07
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease pa···【more】
Recommended：[list:visits]2026-15-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
